Translational Drug Development (TD2) is an oncology-focused Contract Research Organization (CRO) that supports improved and accelerated development of medicines for life-threatening diseases. We help companies move their drugs through the critical stages of preclinical, regulatory and clinical trial processes. Our scientific depth, proactive problem solving, and strategic direction and advice increase the likelihood of positive outcomes that bring hope and a better quality of life to cancer patients and their families. TD2 was born from the Translational Genomics Research Institute (TGen) as a nonprofit in 2003. TGen’s deep scientific expertise and approach to interrogating the “omic” drivers of disease is at the heart of TD2’s heritage and has become the foundation upon which TD2 creates unique clinical strategies for its clients.
External link for Translational Drug Development (TD2)
13208 E Shea Blvd. Suite 100
Scottsdale, Arizona 85259, US
Planning to file an IND in 2025? Our Clinical Trial Enablement Program accelerates your path from filing to enrolling your first patient. By initiating clinical trial planning earlier, we are able to enroll 4+ months faster. Let us handle the details so you can focus on innovation. 🔗https://hubs.li/Q031r19H0 #INDSubmission #ClinicalTrials #DrugDevelopment #ClinicalResearch #Oncology
This content isn’t available here
Access this content and more in the LinkedIn app
🌟 New White Paper Alert! 🌟 TD2 is kicking off the New Year with the release of our latest white paper: "Optimizing Specimen Stability: A Comparative Analysis of Shipping Protocols." In oncology research, the integrity of biospecimens is critical to the accuracy of research and diagnostics. Our comprehensive analysis evaluates various shipping protocols, highlighting the strategies that ensure specimen stability for flow cytometry analysis from lab to destination. Download Now: https://hubs.li/Q031jyn70 #TD2 #flowcytometry #immunophenotyping
As the year comes to a close, we want to take a moment to thank our partners, clients, and team members for their collaboration and dedication. Your contributions continue to drive innovation and progress in oncology research. Wishing you a joyful holiday season and a bright, successful New Year! #HappyHolidays #OncologyResearch
Flow cytometry is an invaluable tool in drug development, providing detailed insights into cellular interactions, identifying biomarkers, and uncovering potential safety concerns. With over 20 years of experience, TD2 offers custom assay development and validation to support both nonclinical and clinical studies. Our new Flow Cytometry FAQ page answers common questions, such as: • Why use flow cytometry in drug development? • What types of assays can TD2 perform? • How are specimens collected and transported? • What deliverables and timelines can you expect? Learn more about how TD2’s expertise can support your research at every stage of drug development. 👉 Explore the FAQ: https://hubs.ly/Q030cVNd0 #FlowCytometry #OncologyResearch #DrugDevelopment
The complexity of cancer demands advanced research models. PDX models in humanized immune systems offer the precision researchers need to evaluate next-generation therapies. These tools unlock insights into tumor-immune interactions that traditional models can’t provide. Read our blog to see how this approach could elevate your oncology studies: The Importance of Conducting PDX Oncology Studies in a Humanized Immune System https://hubs.li/Q03014RB0 #PDXmodels #CancerResearch #TD2 #HumanizedMice
Translational Drug Development (TD2) reposted this
Today's Phoenix TITAN 100 spotlight is on Tara Franks, Chief Operating Officer at Translational Drug Development (TD2). Tara says, “I can look back and rely on the fact that I have always found a path forward, and trusting in that takes away the stress and worry that interferes with my ability to focus on the solution to whatever problem I’m trying to solve and take action.” #Titan100 #TitanCEO #PHOENIX #PHX #leadership #leadershipquotes #businessleadership #success #motivation #mindset #innovation Read more: https://lnkd.in/g7trq6PM
Hematologic malignancies like leukemia and multiple myeloma require more than standard imaging techniques to assess therapeutic progress. Our latest blog explores how flow cytometry provides critical support in these challenging trials, delivering the precise, high-resolution insights needed to drive meaningful results. Here’s what you’ll discover in the blog: ✅ How flow cytometry detects rare and abnormal cell populations with precision. ✅ Insights into monitoring immune system dynamics to optimize therapies like CAR-T. ✅ The role of biomarker discovery in driving personalized treatment strategies. 🔗 https://hubs.li/Q02_f7lF0 TD2 is here to help you understand the power of flow cytometry in advancing cancer research and achieving success in your clinical trials. #FlowCytometry #ClinicalTrials #OncologyResearch #Hematology #HematologicMalignancies #OncologyCRO #BloodCancerResarch #ClinicalResearchSolutions
The latest blog from TD2 highlights the growing importance of incorporating metabolomics and proteomics into preclinical oncology studies. Multi-omic screening provides a comprehensive view of tumor biology, uncovering key insights into metabolic pathways, protein signaling networks, and biomarker development. From enhancing drug efficacy assessments to optimizing combination therapies, these approaches are transforming how researchers address the complexity of cancer. The blog also features a case study leveraging diet-induced obesity mouse models to explore gender-specific and metabolic influences on checkpoint inhibitor efficacy. Learn how metabolomics and proteomics are shaping the future of oncology drug development: https://hubs.li/Q02-BCN20
TD2 is headed to #ASH2024 this weekend! Our Chief Medical Officer, Alan Miller MD, PhD, and Senior Director of Business Development, Parris Johnson, will be in San Diego through the 10th and are eager to discuss your upcoming hematologic malignancy trials. From protocol design and regulatory strategy to advanced flow cytometry, TD2 provides tailored solutions designed to streamline your research and accelerate progress. Schedule a meeting today! 🔗https://hubs.ly/Q02-c2_90 #HematologicMalignancies #ClinicalTrials #BloodCancer #ClinicalResearch #ClinicalTrialSolutions